HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders.

MLA

Wang, Qin, et al. “HPK1 Kinase Inhibitor: A Sufficient Approach to Target HPK1 to Modulate T Cell Activation in Cancer Immunotherapy Compared with Degraders.” Frontiers in Immunology, Feb. 2025, pp. 1–10. EBSCOhost, https://doi.org/10.3389/fimmu.2025.1449106.

APA

Wang, Q., Zhu, X., Li, J., Xu, S., Wang, A., Zhang, X., Wang, X., Cai, X., Xing, H., Liu, Y., Liu, X., Wang, Z., Wang, L., & Yuan, X. (2025). HPK1 kinase inhibitor: a sufficient approach to target HPK1 to modulate T cell activation in cancer immunotherapy compared with degraders. Frontiers in Immunology, 1–10. https://doi.org/10.3389/fimmu.2025.1449106

Chicago

Wang, Qin, Xinyi Zhu, Jing Li, Sanjia Xu, Ali Wang, Xinwen Zhang, Xingxing Wang, et al. 2025. “HPK1 Kinase Inhibitor: A Sufficient Approach to Target HPK1 to Modulate T Cell Activation in Cancer Immunotherapy Compared with Degraders.” Frontiers in Immunology, February, 1–10. doi:10.3389/fimmu.2025.1449106.